Schizophrenia Market to Gain Momentum During the Forecast Period (2026-2036), with Growing Pipeline of Novel and Long-Acting Therapies | DelveInsight

The schizophrenia market is expected to showcase significant growth driven by rising disease prevalence, the expanding market for approved therapies, and the anticipated launch of new schizophrenia treatments such as Olanzapine LAI (TEV-44749/mdc-TJK; Teva Pharmaceutical/MedinCell/Royalty Pharma), Ulotaront (SEP-363856; Sumitomo Pharma/Otsuka Pharmaceuticals), Brilaroxazine (RP-5063; Reviva Pharmaceuticals), and others during the forecast period.

LAS VEGAS, Oct. 7, 2026 /PRNewswire/ — Recently published Schizophrenia Market Insights report includes a comprehensive understanding of current treatment practices, emerging schizophrenia drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

Schizophrenia Market Summary

• The market size of schizophrenia in the 7MM was more than USD 8 billion in 2025, which is further expected to increase by 2036.
• The United States accounted for the largest schizophrenia treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In 2025, the total diagnosed prevalent cases of schizophrenia in the 7MM were found to be nearly 4 million cases, out of which the US accounted for nearly 1.5 million cases.
• Leading schizophrenia companies, such as Teva Pharmaceutical, MedinCell, Royalty Pharma, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Newron Pharmaceuticals, Neurocrine Biosciences, Nxera Pharma, LB Pharmaceuticals, and others, are developing new schizophrenia treatment drugs that can be available in the schizophrenia market in the coming years. 
• The promising schizophrenia therapies in clinical trials include Olanzapine LAI (TEV-44749/mdc-TJK), Ulotaront (SEP-363856), Brilaroxazine (RP-5063), Roluperidone (MIN-101/MT-210), Evenamide (NW-3509), NBI-570, LB-102, and others.

Discover FDA approved medications for schizophrenia with brand and generic names 2026 @ https://www.delveinsight.com/report-store/schizophrenia-market

Key Factors Driving the Growth of the Schizophrenia Market 

• Rising Prevalence of Schizophrenia: The growing prevalence of schizophrenia worldwide is increasing the demand for effective pharmacological treatments and long-term disease management. Greater recognition and diagnosis of the disorder are also expanding the addressable patient population.
• Growing Demand for Novel Antipsychotic Therapies: Limitations associated with existing antipsychotics, including inadequate control of negative and cognitive symptoms and treatment-related adverse effects, are driving the development of next-generation therapies with improved efficacy and tolerability.
• Increasing Focus on Negative and Cognitive Symptoms: Traditional treatments primarily target positive symptoms such as hallucinations and delusions, while negative and cognitive symptoms remain significant unmet needs. This gap is encouraging pharmaceutical companies to develop therapies with broader symptom coverage.
• Expansion of the Clinical Development Pipeline: Pharmaceutical and biotechnology companies are investing in innovative schizophrenia candidates targeting different biological pathways and symptom domains. A growing pipeline of therapies including Olanzapine LAI (TEV-44749/mdc-TJK; Teva Pharmaceutical/MedinCell/Royalty Pharma), Ulotaront (SEP-363856; Sumitomo Pharma/Otsuka Pharmaceuticals), Brilaroxazine (RP-5063; Reviva Pharmaceuticals), Roluperidone (MIN-101/MT-210; Minerva Neurosciences/Mitsubishi Tanabe Pharma), and others is expected to introduce additional treatment options and expand market opportunities.

Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that the market for schizophrenia drugs is driven by increasing demand for long-acting antipsychotic medications, along with the emergence of new molecules in development.

Schizophrenia Market Analysis

• Antipsychotics, which are recommended as the first-line pharmacological treatment for schizophrenia, are broadly classified into first-generation and second-generation agents and remain the primary pharmacological interventions for the disorder. 
• First-generation antipsychotics include chlorpromazine, fluphenazine, haloperidol, and perphenazine. These therapies primarily target positive symptoms, including hallucinations and delusions, but have limited efficacy in addressing negative symptoms and cognitive impairments.
• Second-generation antipsychotics, including REXULTI/RXULTI (brexpiprazole), CAPLYTA (lumateperone), LATUDA (lurasidone hydrochloride), SAPHRIS (asenapine), ABILIFY MYCITE (aripiprazole tablets with sensor), VRAYLAR/REAGILA (cariprazine), SECUADO (asenapine), INVEGA SUSTENNA/TRINZA/HAYFERA (paliperidone palmitate), ARISTADA/ARISTADA INITIO (aripiprazole lauroxil), PERSERIS (risperidone), FANAPT (iloperidone), and LYBALVI (olanzapine and samidorphan), among others, were developed to address positive and negative symptoms as well as neurocognitive manifestations of schizophrenia. 
• Although these agents are generally associated with a lower incidence of extrapyramidal symptoms (EPS), they can cause adverse effects such as weight gain, sexual dysfunction, and other metabolic disorders. In certain patient populations, including older adults, treatment with both first- and second-generation antipsychotics has also been associated with an increased risk of pneumonia.
• In September 2024, the U.S. FDA approved Bristol Myers Squibb’s COBENFY (xanomeline and trospium chloride), formerly known as KarXT, for the treatment of schizophrenia in adults. COBENFY represents the first new pharmacological approach to schizophrenia treatment in decades and has a distinct mechanism of action, targeting M1 and M4 muscarinic receptors in the brain without directly blocking D2 dopamine receptors.
• Several potential therapies are also projected to enter the schizophrenia treatment market during the forecast period. These include Teva Pharmaceutical/MedinCell/Royalty Pharma’s olanzapine LAI (TEV-‘749), Sunovion Pharmaceutical (Sumitomo Pharma)/Otsuka’s ulotaront (SEP-363856), Reviva Pharmaceuticals’ brilaroxazine (RP5063), Minerva Neurosciences/Mitsubishi Tanabe Pharma’s roluperidone (MIN-101/MT-210), and Newron Pharmaceuticals’ evenamide (NW-3509), among others.

Schizophrenia Competitive Landscape

Some of the schizophrenia medications under development include Olanzapine LAI (TEV-44749/mdc-TJK; Teva Pharmaceutical/MedinCell/Royalty Pharma), Ulotaront (SEP-363856; Sumitomo Pharma/Otsuka Pharmaceuticals), Brilaroxazine (RP-5063; Reviva Pharmaceuticals), Roluperidone (MIN-101/MT-210; Minerva Neurosciences/Mitsubishi Tanabe Pharma), Evenamide (NW-3509; Newron Pharmaceuticals), NBI-570 (Neurocrine Biosciences/Nxera Pharma), LB-102 (LB Pharmaceuticals), and others.

Teva Pharmaceutical/MedinCell/Royalty Pharma’s TEV-‘749 (olanzapine) is an investigational, once-monthly, long-acting subcutaneous formulation of the second-generation antipsychotic olanzapine. The product has not received regulatory approval for any indication, and its safety and efficacy have yet to be established. Teva’s schizophrenia portfolio has advanced with the development of TEV-‘749, a once-monthly subcutaneous long-acting injectable formulation designed to provide sustained olanzapine treatment.

Sumitomo Pharma/Otsuka Pharmaceuticals’ Ulotaront (SEP-363856) is an investigational small-molecule, orally administered trace amine-associated receptor 1 (TAAR1) agonist that also exhibits serotonin 5-HT1A agonist activity. Unlike conventional antipsychotics, ulotaront does not bind to dopamine D2 or serotonin 5-HT2A receptors. The drug is being jointly developed and commercialized through a collaboration among Sumitomo Pharma, its U.S. subsidiary Sumitomo Pharma America (SMPA), and Otsuka. SMPA discovered ulotaront in collaboration with PsychoGenics, leveraging a mechanism-independent discovery strategy based partly on the in vivo phenotypic SmartCube platform and associated artificial intelligence algorithms.

Reviva Pharmaceuticals’ Brilaroxazine (RP-5063) is a novel chemical entity with potent affinity and selectivity for key serotonin and dopamine receptors implicated in schizophrenia and other psychiatric disorders. The compound acts as a multimodal modulator of serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT7 receptors, as well as dopamine D2, D3, and D4 receptors, and is undergoing clinical development across multiple neuropsychiatric indications. In addition to schizophrenia, brilaroxazine is being investigated for bipolar disorder, major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), and inflammatory conditions, including pulmonary arterial hypertension, idiopathic pulmonary fibrosis, and psoriasis.

Minerva Neurosciences/Mitsubishi Tanabe Pharma’s Roluperidone (MIN-101) is being developed by Minerva Neurosciences for the treatment of persistent negative symptoms of schizophrenia, which can remain chronic and substantially affect patients’ quality of life and functional outcomes. The drug acts on serotonin and sigma receptors in the brain, which are associated with the regulation of mood, cognition, sleep, and anxiety. Minerva Neurosciences holds a global license for roluperidone from Mitsubishi Tanabe Pharma Corporation, including rights to develop, commercialize, and import the compound, also known as MT-210. Roluperidone has completed Phase III clinical development in the U.S. for the treatment of negative symptoms associated with schizophrenia.

The anticipated launch of these emerging therapies are poised to transform the schizophrenia market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the schizophrenia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about the schizophrenia drugs market @ Schizophrenia Therapies

Recent Developments in the Schizophrenia Market

• In September 2026, Newron Pharmaceuticals S.p.A. announced the completion of patient screening for enrollment in its pivotal Phase III ENIGMA-TRS 1 study.
• In May 2026, Teva Pharmaceuticals and Medincell announced that the European Medicines Agency (EMA) has accepted their Marketing Authorization Application (MAA) for olanzapine long-acting injectable (TEV-‘749), intended for the treatment of schizophrenia in adults.
• In March 2026, Minerva Neurosciences, Inc. announced the screening of the first patient in its global, confirmatory Phase 3 clinical trial assessing roluperidone as a monotherapy for the treatment of negative symptoms associated with schizophrenia.
• In March 2026, LB Pharmaceuticals Inc. announced the initiation of its pivotal Phase 3 NOVA-2 trial to evaluate the efficacy and safety of LB-102 for the treatment of schizophrenia.
• In February 2026, the US FDA accepted Teva Pharmaceutical Industries’s New Drug Application (NDA) for its investigational drug, olanzapine extended-release injectable suspension (TEV-‘749), which is intended for once-monthly treatment of schizophrenia in adults.
• In January 2026, Reviva announced the publication of clinical vocal biomarker data from the RECOVER Phase III clinical trial of brilaroxazine to treat negative symptoms in schizophrenia.

Schizophrenia Epidemiology Segmentation

The schizophrenia epidemiology section provides insights into the historical and current schizophrenia patient pool and forecasted trends for the leading markets. Most schizophrenia patients globally do not receive mental health care. Around 50% of mental hospital patients have schizophrenia, but only 31.3% of those with psychosis receive specialized care.

The schizophrenia treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Prevalent Cases of Schizophrenia
• Total Diagnosed Prevalent Cases of Schizophrenia
• Gender-specific Diagnosed Prevalent Cases of Schizophrenia
• Severity-specific Diagnosed Prevalent Cases of Schizophrenia

Scope of the Schizophrenia Market Report

• Schizophrenia Patient Population Forecast
• Schizophrenia Therapeutics Market Size
• Schizophrenia Pipeline Analysis
• Schizophrenia Market Size and Trends
• Schizophrenia Market Opportunity
• Schizophrenia Market Unmet Needs
• KOL’s Views on Schizophrenia
• Schizophrenia Market Access and Reimbursement

Download the report to understand medications used to treat schizophrenia @ Schizophrenia Clinical Trials

Table of Contents

Related Reports

Schizophrenia Clinical Trial Analysis

Schizophrenia Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key schizophrenia companies, including Sunovion Pharmaceuticals, Denovo BioPharma, Cyclerion Therapeutics, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals, and others.

Cognitive Impairment Associated with Schizophrenia Market

Cognitive Impairment Associated with Schizophrenia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cognitive impairment associated with schizophrenia companies, including Boehringer Ingelheim, Recognify Life Sciences, Alto Neuroscience, MEDRx, Kynexis, Gabather AB, and others.

Bipolar Depression Market

Bipolar Depression Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bipolar depression companies, including Xenon Pharmaceuticals, Autobahn Therapeutics, AbbVie, Alto Neuroscience, NRx Pharmaceuticals, LB Pharmaceuticals, and others.

Alzheimer’s Disease Market

Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer’s disease companies, including ARS Pharmaceuticals, Alfresa Pharma, Roche, Stallergenes Greer, DBV Technologies, Aquestive Therapeutics, Aravax, Siolta Therapeutics, GSK, Cue Biopharma, N-Fold, InnoUp Farma, Allergy Therapeutics, UKKO, Bryn Pharma, Poplar Therapeutics, Inimmune, Novartis (Excellergy), Intrommune Therapeutics, Regeneron Pharmaceuticals, Sanofi, Moonlight Therapeutics, Mabylon AG, Insignis Therapeutics, ALK-Abello, Cambridge Allergy, Prota Therapeutics, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur

[email protected]

+14699457679

www.delveinsight.com

 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/schizophrenia-market-to-gain-momentum-during-the-forecast-period-20262036-with-growing-pipeline-of-novel-and-long-acting-therapies–delveinsight-302900631.html

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. UK Newshour takes no editorial responsibility for the same.